Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade C 15.95 3.91% 0.60
SGMO closed up 3.91 percent on Thursday, September 20, 2018, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical SGMO trend table...

Date Alert Name Type % Chg
Sep 20 Crossed Above 20 DMA Bullish 0.00%
Sep 20 MACD Bullish Signal Line Cross Bullish 0.00%
Sep 20 Wide Bands Range Expansion 0.00%
Sep 20 Up 3 Days in a Row Strength 0.00%
Sep 19 20 DMA Resistance Bearish 3.91%
Sep 19 Narrow Range Bar Range Contraction 3.91%
Sep 19 Wide Bands Range Expansion 3.91%
Sep 18 Crossed Above 50 DMA Bullish 4.93%
Sep 18 Wide Bands Range Expansion 4.93%
Sep 17 Bearish Engulfing Bearish 8.50%

Older signals for SGMO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.5
52 Week Low 11.3
Average Volume 2,437,815
200-Day Moving Average 17.6214
50-Day Moving Average 14.999
20-Day Moving Average 15.5225
10-Day Moving Average 14.835
Average True Range 0.9379
ADX 14.7
+DI 27.6086
-DI 23.756
Chandelier Exit (Long, 3 ATRs ) 16.4363
Chandelier Exit (Short, 3 ATRs ) 15.4137
Upper Bollinger Band 18.4691
Lower Bollinger Band 12.5759
Percent B (%b) 0.57
BandWidth 37.965534
MACD Line -0.042
MACD Signal Line -0.0476
MACD Histogram 0.0056
Fundamentals Value
Market Cap 1.34 Billion
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -19.69
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.85
Resistance 3 (R3) 16.75 16.35 16.70
Resistance 2 (R2) 16.35 16.12 16.40 16.65
Resistance 1 (R1) 16.15 15.98 16.25 16.25 16.60
Pivot Point 15.75 15.75 15.80 15.80 15.75
Support 1 (S1) 15.55 15.52 15.65 15.65 15.30
Support 2 (S2) 15.15 15.38 15.20 15.25
Support 3 (S3) 14.95 15.15 15.20
Support 4 (S4) 15.05